

LABORATORY CORP OF AMERICA HOLDINGS

Form 8-K

April 18, 2019

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**  
**PURSUANT TO SECTION 13 OR 15(d)**  
**OF THE SECURITIES EXCHANGE ACT OF 1934**

**April 17, 2019**

**(Date of earliest event reported)**

**LABORATORY CORPORATION OF AMERICA HOLDINGS**

**(Exact Name of Registrant as Specified in its Charter)**

**Delaware**  
**(State or other jurisdiction**  
  
**of Incorporation)**

**1-11353**  
**(Commission**  
  
**File Number)**

**13-3757370**  
**(I.R.S. Employer**  
  
**Identification No.)**

**358 South Main Street,**

**Burlington, North Carolina**  
**(Address of principal executive**  
**offices)**

**27215**  
**(Zip Code)**

**336-229-1127**  
**(Registrant's telephone number**  
**including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure**

LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, and Envigo, a leading provider of nonclinical contract research services and research models, announced on April 17, 2019 that LabCorp's Covance Drug Development segment will acquire Envigo's nonclinical research services business, and Envigo's Research Models Services business will acquire the Covance Research Products business. This transaction will result in Envigo becoming a pure-play research models and services business, while Covance will expand its global nonclinical drug development capabilities. A copy of the press release announcing this transaction has been furnished as Exhibit 99.1 to this Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

**(d) Exhibits**

- 99.1 Press Release, dated April 17, 2019, jointly issued by Laboratory Corporation of America Holdings and Envigo International Holdings, Inc.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF  
AMERICA HOLDINGS

By: /s/ SANDRA D. VAN DER VAART  
Sandra D. van der Vaart  
Senior Vice President, Global General  
Counsel and Secretary

April 17, 2019

**EXHIBIT INDEX**

**Exhibit  
No.**

**Description**

99.1	Press Release, dated April 17, 2019, jointly issued by Laboratory Corporation of America Holdings and Envigo International Holdings, Inc.
------	---